Accessibility Tools

Medication Legend

℞: Medications that treat viral infections and tumors are marked with the "℞" symbol.
+: Medications that contain proteins for weight gain are marked with the "+" symbol.
++: Regenerative medications for neurogenesis are marked with the "++" symbol.

This ISS National Lab Research Announcement (NLRA) is issued in collaboration with NASA’s Division of Biological and Physical Sciences (BPS) and seeks proposals for flight research on the ISS to address the goals of the Cancer MoonshotSM initiative and accelerate the translation of stem cell- and organoid-based disease models and advanced technologies for biomanufacturing.

CASIS intends to select for award spaceflight projects leading to defined milestones in technological innovation on a roadmap that aligns with national R&D priorities and the ISS National Lab mission to benefit humanity and the U.S. economy. In evaluating proposals, CASIS prioritizes the scientific and technical merit of the proposal as well as its feasibility and potential benefit to value creation for the nation and the emerging LEO space ecosystem. The ISS National Lab strives for a balanced project award portfolio that accounts for diverse factors, including, but not limited to, different types of institutional representation, participation by individuals traditionally underrepresented in STEM areas and careers, and the assembly of teams promote inclusion, diversity, equity, and accessibility (IDEA) for improving workforce development.

This research announcement will follow a three-step proposal submission process. All interested investigators must first complete and submit for review a Step 1A: Concept Summary. Offerors with approved concepts will be invited to submit a Step 1B: Technology Roadmap. Offerors with approved Technology Roadmaps will then be invited to submit a Step 2: Full Proposal.

APPLICANT RESOURCES

Click here to view Applicant Resources for ISS National Lab Research Opportunities

FREQUENTLY ASKED QUESTIONS
Click here to view frequently asked questions regarding NLRA 2023-10.

WEBINAR

  • Step 1A: Download NLRA 2023-10 Instructions and Required Step 1A Forms

    Download Step 1A Required Forms

    • The deadline for submissions has passed

    Upload your Step 1A: Concept Summary by pressing the “Upload Step 1A Submission” button below. Please convert your document to a PDF prior to uploading.

    Upload Step 1A Submission

  • Step 1B: Download NLRA 2023-10 and Required Step 1B Forms (Invitation Only)

    CASIS will notify all offerors of the review results of their Step 1A: Concept Summary.

    Download Step 1B Required Forms

    • Step 1B: Technology Roadmap Due Date: November 29, 2023

    Upload your Step 1B: Concept Summary by pressing the “Upload Step 1B Submission” button below. Please convert your document to a PDF prior to uploading.

    Upload Step 1B Submission

  • Step 2.1: Download Step 2 Required Forms (Invitation Only)

    CASIS will notify all offerors of the review results of their Step 1B: Technology Roadmap.

    Download Step 2 Required Forms

    Full proposal development periods for Invited Step 2: Full Proposals

    • Update: Step 2: Full Proposal Due Date: March 15, 2024
  • Step 2.2: Full Proposal Submission

    If you were invited to submit a Step 2: Full Proposal, upload your submission by pressing the “Click to Submit” button below. Please convert your document to a PDF prior to uploading. Offerors should ensure they are using a current version of Adobe Acrobat to create their PDF and that uploaded documents do not include Flash content.

    CLICK TO SUBMIT

Thank you for your interest in conducting research through the ISS National Lab. For questions regarding this research announcement, please contact [email protected] and reference NLRA2023-10 in the subject line.

** Please verify that none of the information submitted is subject to the export control laws of the United States, such as the EAR or the ITAR; if any information is subject to such laws, please mark all pages containing such information and identify the appropriate export control jurisdiction and classification. **

Content Original Link:

https://www.issnationallab.org/research-on-the-iss/solicitations/nlra2023-10/

Access Non-GMO, antigen-free, FDA-approved antiviral medication formulas used in Moderna's Spikevax.

VirusTC is a retail provider of concentrated FDA-approved antiviral medication formulas. VirusTC wholesale formulas are used in Moderna products. We sell FDA-approved formulas that are compatible with university medical plans, federal insurance coverage, and many major insurance providers. Our medications are part of tailored non-invasive cancer treatment plans available at a hospital in your region. VirusTC targets problems and provides care for the symptoms. Our products and services are used by Fred Hutch Cancer Center, John Hopkins, University Hospitals, the United States Military, and professional sports. During Operation Cancer Moonshot 2023, VirusTC products killed cancer cells, increased strength, and redeveloped muscles, tissue, and brain cells after cancer treatments.